全文获取类型
收费全文 | 110914篇 |
免费 | 7482篇 |
国内免费 | 572篇 |
专业分类
耳鼻咽喉 | 1335篇 |
儿科学 | 2573篇 |
妇产科学 | 1644篇 |
基础医学 | 14244篇 |
口腔科学 | 2938篇 |
临床医学 | 10700篇 |
内科学 | 24408篇 |
皮肤病学 | 1706篇 |
神经病学 | 10604篇 |
特种医学 | 4316篇 |
外国民族医学 | 2篇 |
外科学 | 18884篇 |
综合类 | 866篇 |
一般理论 | 198篇 |
预防医学 | 7482篇 |
眼科学 | 2133篇 |
药学 | 6741篇 |
1篇 | |
中国医学 | 218篇 |
肿瘤学 | 7975篇 |
出版年
2023年 | 1007篇 |
2022年 | 1762篇 |
2021年 | 3807篇 |
2020年 | 2099篇 |
2019年 | 3276篇 |
2018年 | 3853篇 |
2017年 | 2727篇 |
2016年 | 2931篇 |
2015年 | 3309篇 |
2014年 | 4530篇 |
2013年 | 5773篇 |
2012年 | 8725篇 |
2011年 | 8867篇 |
2010年 | 4900篇 |
2009年 | 4268篇 |
2008年 | 7200篇 |
2007年 | 7042篇 |
2006年 | 6713篇 |
2005年 | 6595篇 |
2004年 | 5866篇 |
2003年 | 5375篇 |
2002年 | 4803篇 |
2001年 | 830篇 |
2000年 | 724篇 |
1999年 | 872篇 |
1998年 | 976篇 |
1997年 | 785篇 |
1996年 | 627篇 |
1995年 | 616篇 |
1994年 | 498篇 |
1993年 | 487篇 |
1992年 | 477篇 |
1991年 | 427篇 |
1990年 | 381篇 |
1989年 | 360篇 |
1988年 | 368篇 |
1987年 | 336篇 |
1986年 | 356篇 |
1985年 | 339篇 |
1984年 | 402篇 |
1983年 | 348篇 |
1982年 | 368篇 |
1981年 | 364篇 |
1980年 | 284篇 |
1979年 | 184篇 |
1978年 | 210篇 |
1977年 | 197篇 |
1975年 | 158篇 |
1974年 | 160篇 |
1973年 | 152篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. 总被引:3,自引:0,他引:3
Joachim Wernicke Alberto Lledó Joel Raskin Daniel K Kajdasz Fujun Wang 《Drug safety》2007,30(5):437-455
BACKGROUND AND OBJECTIVE: In recent years, new classes of medication, such as the serotonin-noradrenaline reuptake inhibitors (SNRIs), have been developed for use in the treatment of major depressive disorder (MDD). For many years, treatment options were largely limited to the use of monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). However, there have been published reports of orthostatic hypotension, arrhythmias and corrected QT (QTc) interval changes in patients treated with TCAs. As new medications become available, it is important to understand how their cardiovascular safety profile compares with that of more established agents to aid clinicians and patients in choosing the best treatment options. This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs). METHODS: The cardiovascular safety of duloxetine was assessed using all placebo-controlled duloxetine clinical trial data as of December 2005. This consisted of data from 42 placebo-controlled clinical trials of 8504 patients who were treated with duloxetine. Additional information from a high-dose clinical pharmacology study and postmarketing safety surveillance are also presented. Of the placebo-controlled trials included in this analysis, clinical indications under investigation included MDD (15 studies), diabetic peripheral neuropathic pain (3 studies), fibromyalgia (2 studies), generalised anxiety disorder (3 studies) and lower urinary tract disorders (19 studies, all related to incontinence). Cardiovascular safety was evaluated based on vital signs, ECGs and the incidence of treatment-emergent AEs potentially related to cardiovascular safety. These safety parameters were analysed across all indications. To identify both serious and non-serious cardiovascular-related AEs, as well as AEs reported as the reason for discontinuation, a comprehensive list of terms derived from the Medical Dictionary for Regulatory Activities (version 8.0) was generated and used to search the duloxetine databases for cardiovascular-related events. RESULTS: Calculation of change from baseline to maximum in ECG parameters showed significant differences between treatment groups for all parameters, with decreases from baseline in RR, QRS and QT intervals for patients receiving duloxetine and increases from baseline for patients treated with placebo. These shifts were related to small heart rate changes, but the mean differences were not considered clinically relevant. Categorical analyses of shifts from normal to abnormal (or abnormal to normal) for heart rate and QT corrected for heart rate using Fridericia's formula (QTcF) values showed that most patients did not shift from their baseline category. Patients with MDD who were treated for up to 1 year with duloxetine had blood pressure changes early in treatment that then stabilised. Even in patients with elevated blood pressure at baseline in these clinical trials, no increased risk of sustained blood pressure elevation with duloxetine treatment was found. CONCLUSION: Overall, the findings presented here support our conclusions that use of duloxetine does not appear to be associated with significant cardiovascular risks in patients with conditions for which the drug has been approved or studied. 相似文献
74.
The effect of laser refractive surgery on the on-field performance of professional baseball players.
BACKGROUND: The aim of this study was to determine the effect of laser refractive surgery on the offensive performance of professional baseball players. METHODS: Extensive search of the public media was conducted to determine which major league baseball players had undergone laser refractive surgery and when the procedure was performed. Baseball performance data were then used to determine presurgery and postsurgery baseball performance averages. A total of 17 position players were identified; however, 5 of these players were not considered in the analysis owing to insufficient playing experience either before or after the laser procedure. RESULTS: No statistically significant or practically significant difference was found between the presurgery and postsurgery means on either on-base percentage (P = 0.31), batting average (P = 0.39), slugging percentage (P = 0.66) or on-base plus slugging (OPS; P = 0.997) of major league baseball players. CONCLUSIONS: These preliminary findings suggest that professional baseball players should not expect a laser refractive surgical procedure to significantly improve their offensive baseball performance, despite the elimination of glasses or contact lens wear. 相似文献
75.
Daniel J. Weisdorf Martin M. Oken Gerhard J. Johnson Robert E. Rydell 《American journal of hematology》1981,11(4):397-402
Twenty-five patients with refractory anemia with excess blasts (RAEB) were studied. Five of these patients showed Auer rods in their myeloblasts, but met other criteria for RAEB. Median survival of the Auer rod-positive group was 14 months (range 2–27) from diagnosis with survival of 7 months after Auer rods were first observed. Median survival for the Auer rod-negative group was 12 months. Two patients developed overt acute leukemia, both from the Auer rod-negative group. The clinical course of Auer rod-positive RAEB, like that of Auer rod-negative RAEB, was one of progressive bone marrow failure complicated by infection, serious bleeding and the development of absolute transfusion requirement. These findings suggest that Auer rod-positive RAEB is a morphologic variant dysmyelopoietic syndrome that may pursue a similar clinical course to Auer rod-negative disease. Formulation of a separate treatment approach for those RAEB patients who possess Auer rods would appear ill advised. 相似文献
76.
A likelihood ratio statistic is proposed for combining two-point genetic linkage analyses when the two-point analyses are between a trait and a well-defined map of markers. It is assumed that the two-point analyses are independent, as in the case of choosing only the most informative marker per family. The asymptotic distribution of the likelihood ratio statistic is derived under the null hypothesis of no linkage of the trait with a map of 2 markers, with intermarker genetic distance δ. This distribution is shown to be a chi-square mixture distribution with mixing probability depending on δ and the assumed mapping function. We use this asymptotic result to approximate the distribution of the likelihood ratio statistic for the more general case of more than 2 markers. Simulation results indicate that this may be reasonable. Power is evaluated by simulations and results indicate that this approach, which constrains the intermarker distances to their known values, tends to be more powerful than other methods proposed in the literature. © 1994 Wiley-Liss, Inc. 相似文献
77.
78.
Jack Yamuy John K. Engelhardt Francisco R. Morales Michael H. Chase 《Brain research》1992,570(1-2):300-306
The objective of this study was to determine whether the aging process influences the changes in the electrophysiological properties of motoneurons that occur as a consequence of axotomy. Accordingly, using intracellular recording and stimulating techniques, the basic electrical properties of control (unaxotomized) and axotomized spinal cord motoneurons of aged cats were determined. Compared with control motoneurons, axotomized motoneurons exhibited increases in input resistance (Rin), membrane time constant (τb) and the equalizing time constant (τc). While the electrotonic length (L) remained unchanged, axotomy induced a decrease in the total cell capacitance (Ccell. The post-axotomy reduction of Ccell indicates that the motoneuron surface area was reduced and the increased membrane time constant indicates that there was an increase in membrane resistivity (Rm). The post-axotomy conservation of L accompanied by an increase in Rm suggests that aged axotomized motoneurons undergo geometrical changes. Furthermore, calculations based on cable theory suggest that the diameter of the equivalent cylinder (d) decreased following axotomy, whereas the equivalent cylinder length (l) remained unaffected. It is concluded that axotomy produces significant alterations in the soma-dendritic portion of aged spinal motoneurons, as indicated by the changes found in their passive electrophysiological properties, and that the pattern of the response that occurs in axotomized motoneurons of adult cats is also present in axotomized motoneurons of aged animals. 相似文献
79.
Superficial bladder cancer is one of the few solid human malignancies in which immunotherapy has been proved to be effective. Bacillus Calmette-Guérin was the vaccine which opened the door for this innovative approach. In an era of remarkable achievements in biotechnology, it is truly amazing that this throwback to the Stone Age of tumor immunology has not yet been replaced by a more (or equally) effective substitute. Potential candidates are already on the horizon and deserve a comprehensive evaluation. They must show not only that they are devoid of significant adverse effects but that they possess, beyond a doubt, superior antineoplastic activity. Even more remarkable is that one of the oldest vaccines still in use could emerge in a new role as an effective antineoplastic agent. Bacillus Calmette-Guérin has demonstrated an uncanny capacity for effectiveness as therapy for human diseases. Its protective effect against tuberculosis is well recognized, and its contribution to cancer therapy is widely known. A new and increasing repertoire has recently been presented: two separate groups of researchers have employed the vaccine successfully as a vehicle to express antigen-encoded genes from other pathogens. The exciting aspect of these recent studies resides in the demonstration that the altered vaccine is able to induce humoral and cell-mediated immune responses to the recombinant antigens, including the human immunodeficiency virus (HIV). Thus, BCG once more attracts enormous interest from the scientific community for its versatility and potential as a therapeutic agent. 相似文献
80.